Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1065-1080
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065
Observation | Univariate | Multivariate | ||||
P | HR | 95%CI | P | HR | 95%CI | |
Model 1a | ||||||
MLH1/MSH2 negative | ||||||
Operation vs Operation + Chemotherapy | 0.098 | 1.021 | 0.342-2.741 | 0.147 | 1.563 | 0.481-4.441 |
MLH1/MSH2 positive | ||||||
Operation vs Operation + Chemotherapy | 0.081 | 1.899 | 0.127-4.114 | 0.070 | 1.267 | 0.212-5.052 |
Model 2b | ||||||
MLH1/MSH2 negative | ||||||
Operation vs Operation + Chemotherapy | 0.001 | 4.393 | 2.068-12.316 | < 0.001 | 7.660 | 2.974-15.883 |
MLH1/MSH2 positive | ||||||
Operation vs Operation + Chemotherapy | 0.063 | 2.015 | 0.648-5.997 | 0.052 | 2.817 | 0.223-6.671 |
- Citation: Wang SM, Jiang B, Deng Y, Huang SL, Fang MZ, Wang Y. Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer. World J Gastrointest Oncol 2019; 11(11): 1065-1080
- URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1065.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1065